State of Tennessee Department of Treasury Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

State of Tennessee Department of Treasury lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 37,200 shares of the biopharmaceutical company's stock after selling 1,661 shares during the quarter. State of Tennessee Department of Treasury's holdings in Regeneron Pharmaceuticals were worth $26,499,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rakuten Securities Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the last quarter. OFI Invest Asset Management acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $28,000. Avalon Trust Co bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $36,000. Crowley Wealth Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $36,000. Finally, Private Wealth Management Group LLC grew its holdings in shares of Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after buying an additional 39 shares during the period. Institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

REGN has been the subject of several research analyst reports. Bank of America decreased their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $1,004.00 to $975.00 and set a "buy" rating on the stock in a research report on Wednesday. BMO Capital Markets dropped their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a report on Tuesday, February 4th. UBS Group cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their target price for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $945.32.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded up $2.88 on Friday, reaching $602.64. 964,377 shares of the company's stock traded hands, compared to its average volume of 724,654. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a 50-day simple moving average of $637.38 and a 200 day simple moving average of $721.91. The stock has a market cap of $65.88 billion, a PE ratio of 15.74, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $11.86 earnings per share. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.